Cardioembolic stroke. Primary and secondary prevention.
Modern prospective trials have recently shown that warfarin prescribed to produce less anticoagulant effect than was customary in the past reduces cardioembolic stroke by up to 80% in patients with nonvalvular atrial fibrillation. These results represent a major advance in stroke prevention. The effectiveness of antithrombotic treatment in other settings in which there is risk of cardioembolism is less well established but likely to be substantial.